# Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

> **NCT06635824** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Genmab** · enrollment: 191 (actual)

## Conditions studied

- PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

## Interventions

- **DRUG:** Acasunlimab
- **DRUG:** Pembrolizumab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT06635824
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-25
- **Primary completion:** 2027-07-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 191 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06635824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06635824, "Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06635824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*